

EyePoint Corporate Compliance

Our mission to develop and commercialize innovative ophthalmic products in indications with high unmet medical needs to help improve the lives of patients with serious eye disorders cannot be met without total commitment to compliance in all areas of our business. EyePoint proactively implements an effective compliance program designed to meet external requirements, guided by our core values of integrity, a focus on our employees, a patient first mentality, a team focus and results driven approach and an unwavering commitment to innovation.

EyePoint's compliance program is a central component of how business is conducted and is based on the "Commercial Compliance Program Guidance for Pharmaceutical Manufacturers," published by the Office of Inspector General (OIG), U.S. Department of Health and Human Services (DHHS), and the "Code on Interactions with Healthcare Professionals," published by Pharmaceutical Research and Manufacturers of America (PhRMA). The fundamental elements of our compliance program are outlined below.

Compliance Leadership

EyePoint has identified an individual who is responsible for developing, operating and monitoring the compliance program. This person reports to the President/CEO of EyePoint and has direct access to the Board of Directors regarding all compliance concerns.

Documented Policies and Procedures

EyePoint has documented policies and procedures that address the Company's expectations regarding adherence to all applicable laws and regulations. These policies and procedures address the risk areas identified in the OIG guidance as well as other areas specific to EyePoint activities.

Training

EyePoint is dedicated to an ongoing training and education program for its associates with regard to their legal and ethical obligations. EyePoint trains its associates on its Code of Business Conduct and specific risk areas related to each associate's responsibilities. The training program is subject to review and modification as deemed appropriate by the company.

Communication

EyePoint encourages free flow of concerns from Associates with regard to its business activities. All associates have access to report potential instances of fraud and abuse or other instances of potential violation of law, regulations or company policy and procedures. These reports may be submitted through their management, compliance, human resources, or legal. In addition, EyePoint has established a hotline which is available 24 hours a day, 7 days a week, to report potential violations of laws, policies and procedures. If desired, the individual may submit reports anonymously.

To report any potential compliance concerns, please contact the Compliance Hotline at the number or email address below.

855-645-5380 or www.eyepointpharma.ethicspoint.com.

EyePoint does not tolerate any form of retaliation against individuals who report in good faith potential improper, unethical or illegal conduct.

Auditing and Monitoring

EyePoint's compliance program includes ongoing internal efforts to assess, evaluate, monitor, and audit compliance with the Company's policies and procedures. The results of these activities are reported to management.

Corrective Action

EyePoint has an established disciplinary process for those employees who violate the law, regulations or Company policy and procedures. The company will investigate the matter based on the nature of the violation and consider discipline to address the violation and prevent or correct where necessary. In addition to imposing appropriate disciplinary action, the company also assesses whether a violation may be due in part to gaps in EyePoint's, policies, procedures, training, business practices and other controls. If so, the company is committed to implementing corrective and preventative measures to enhance its controls to prevent further violations.

Annual Declaration of Compliance for Purposes of California Health & Safety Code Sections 119400-119402

EyePoint has developed a Comprehensive Compliance Program (CCP) in accordance with the requirements of California Health & Safety Code sections 119400-119402. As of December 1, 2018, EyePoint hereby declares in good faith that it is, in all material respects, in compliance with its CCP and the requirements of California Health & Safety Code §§ 119400-119402. EyePoint has developed and implemented elements of its CCP to address certain issues uniquely raised by the California law. In addition, compliance is a dynamic concept and, therefore, EyePoint periodically assesses the effectiveness of its CCP and may modify aspects of the CCP to enhance it. For a copy of this declaration and a description of EyePoint's CCP, call 617-972-6370.

In accordance with California Health and Safety Code section 119402(d)(1), EyePoint has established an annual limit of \$2,500 for spending on promotional items and activities provided to a health care professional licensed in California. Such items generally are provided to physicians and certain other health care professionals in order to facilitate an educational or scientific discussion about the company's products, the company's research and development efforts, and other health care-related issues. EyePoint's limit also includes educational items provided to a physician (such as a medical textbook) that are intended to benefit patient care. Additionally, pursuant to California Health & Safety Code § 119402(d)(2) and (3), drug samples given to healthcare professionals intended for free

distribution to patients, EyePoint financial support for continuing medical education forums, financial support for health educational scholarships, and fair market value payments made for legitimate services provided by a health care medical professional to EyePoint, including but not limited to consulting, have also been excluded from the spending limit. This stated limit is not a goal, but a maximum that the company sets for itself as a limitation. In most cases, the amounts actually spent are significantly less than the maximum amount set by this limitation. EyePoint may change this spending limit upon review at the discretion of the Company.